收藏切换
A rapid health technology assessment of dienogest on endometriosis
收藏切换
Boran DU1, Xiangjun SHI2, Xueyan ZHANG1, Ran WANG1, Chenghong YIN1, *, Xin FENG1, *
World Clinical Drug | 2024, 45(2) : 153 - 161
Less
收藏切换
World Clinical Drug | 2024, 45(2): 153-161
• Article •
A rapid health technology assessment of dienogest on endometriosis
Full
Boran DU1, Xiangjun SHI2, Xueyan ZHANG1, Ran WANG1, Chenghong YIN1, *, Xin FENG1, *
Affiliations
  • 1.Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University/Beijing Maternal and Child Health Care Hospital, Beijing 100026, China
  • 2.Department of Rheumatology and Clinical Immunology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
Published: 2024-02-10 doi: 10.13683/j.wph.2024.02.008
Outline
收藏切换
Objective

To operate a rapid health technology assessment for treatment of endometriosis with dienogest, providing evidence for clinical evaluation and decision-making.

Methods

The researches of dienogest on endometriosis were searched in Pubmed, Embase, CNKI, Wanfang and other databases. AMSTAR, OQAQ and CHEERS (2022) were used to evaluate the methodological quality of health economics, and the treatment of endometriosis with dienogest was comprehensive evaluated.

Results

The comprehensive evaluation results showed that dienogest had obvious advantages in preventing recurrence rate and improving pain after endometriosis surgery compared with expectant treatment, and was comparable to gonadotrophin releasing hormone analogue (GnRH-a). On safety evaluation, compared with other therapeutic drugs, dienogest had a higher risk of vaginal bleeding, and the risk of headache and weight gain also should be noted, while the risk of hot flashes, vaginal dryness and osteoporosis was relatively small. From perspective of medical insurance payment, dienogest was more cost-effective compared with GnRH-a, but had no advantage compared with combined oral contraceptives (COC).

Conclusion

Dienogest could be used as a long-term maintenance treatment after endometriosis surgery. However, compared with other treatments such as GnRH-a and COC, the efficacy, safety, and pharmacoeconomics of dienogest should be further explored.

dienogest  /  endometriosis  /  rapid health technology assessment  /  health economic evaluation
杜博冉, 史湘君, 张雪艳, 王然, 阴赪宏, 冯欣. 地诺孕素治疗子宫内膜异位症的快速卫生技术评估. 世界临床药物, 2024 , 45 (2) : 153 -161 . DOI: 10.13683/j.wph.2024.02.008
Boran DU, Xiangjun SHI, Xueyan ZHANG, Ran WANG, Chenghong YIN, Xin FENG. A rapid health technology assessment of dienogest on endometriosis[J]. World Clinical Drug, 2024 , 45 (2) : 153 -161 . DOI: 10.13683/j.wph.2024.02.008
Year 2024 volume 45 Issue 2
11
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.02.008
  • Receive Date:2023-09-13
  • Online Date:2026-11-18
  • Published:2024-02-10
Article Data
Affiliations
History
  • Received:2023-09-13
Funding
Affiliations
    1.Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University/Beijing Maternal and Child Health Care Hospital, Beijing 100026, China
    2.Department of Rheumatology and Clinical Immunology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.02.008
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT